The University Of Bristol investment portfolio

Azul Optics develops the MP‑eye, a medical screening device that quantifies patients’ risk from damaging light and provides a score used by eyecare professionals to recommend protective products such as sunglasses, photochromic and blue‑light filtering lenses, and macular pigment supplements. The device is marketed to optometrists, ophthalmologists and other eye‑care practitioners to help prevent eye disease.

Halo Therapeutics Ltd develops self‑administered antiviral therapies, including an intranasal spray, that target SARS‑CoV‑2 and other coronaviruses for early treatment and prophylaxis. Its products are intended for patients experiencing the first signs of COVID‑19 and for broader coronavirus infection prevention.